SNGX - Soligenix, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

SNGX

SOLIGENIX, INC.

NASDAQ

$0.38

▼ DOWN 0.84% (-0.00)

KEY STATISTICS

Market Cap$5.59 M

52w High$3.22

52w Low$0.28

Dividend Yield—

Frequency—

P/E-0.28

Volume139.02K

Shares Out.14.82M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Christopher J. Schaber

COMPENSATION 2026

Salary$200,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$200,000

ABOUT

SECTOR

Healthcare

WENT PUBLIC

April 4, 1994

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 6, 2026

DayFriday

Rev. Est.—

NOV

FRI

SPLIT RECORD

DATE	TYPE	RATIO
2024-06-06	Reverse	1:16
2023-02-10	Reverse	1:15
2016-10-07	Reverse	1:10
2012-02-01	Reverse	1:20
1997-06-20	Reverse	1:15
1997-06-11	Reverse	1:15
1995-12-06	Reverse	1:100

PRICE

$0.38 ▼ DOWN 0.84% (−$0.00)

OVERLAYS

About Soligenix, Inc.

https://www.soligenix.com ↗

Soligenix, Inc. is a late-stage biopharma company developing treatments for rare diseases and public health solutions, including therapies for cancer, inflammatory, infectious diseases, and vaccines.

INDUSTRY

Biotechnology

A PRODUCT SOLIGENIX, INC. IS KNOWN FOR

HyBryte™ (synthetic hypericin)

Soligenix's leading product is a late-stage topical photodynamic therapy using synthetic hypericin, activated by visible light, for treating early-stage cutaneous T-cell lymphoma (CTCL).